These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 19736185)
1. World Health Organization Class III COPD-associated pulmonary hypertension: are we there yet in understanding the pathobiology of the disease? Steiner MK Chest; 2009 Sep; 136(3):658-659. PubMed ID: 19736185 [No Abstract] [Full Text] [Related]
2. Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. Eddahibi S; Chaouat A; Tu L; Chouaid C; Weitzenblum E; Housset B; Maitre B; Adnot S Proc Am Thorac Soc; 2006 Aug; 3(6):475-476. PubMed ID: 16921112 [No Abstract] [Full Text] [Related]
3. Role for interleukin-6 in COPD-related pulmonary hypertension. Chaouat A; Savale L; Chouaid C; Tu L; Sztrymf B; Canuet M; Maitre B; Housset B; Brandt C; Le Corvoisier P; Weitzenblum E; Eddahibi S; Adnot S Chest; 2009 Sep; 136(3):678-687. PubMed ID: 19349390 [TBL] [Abstract][Full Text] [Related]
5. Distinct differences in gene expression patterns in pulmonary arteries of patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis with pulmonary hypertension. Hoffmann J; Wilhelm J; Marsh LM; Ghanim B; Klepetko W; Kovacs G; Olschewski H; Olschewski A; Kwapiszewska G Am J Respir Crit Care Med; 2014 Jul; 190(1):98-111. PubMed ID: 24918967 [TBL] [Abstract][Full Text] [Related]
6. Systemic inflammation in patients with COPD and pulmonary hypertension. Joppa P; Petrasova D; Stancak B; Tkacova R Chest; 2006 Aug; 130(2):326-33. PubMed ID: 16899829 [TBL] [Abstract][Full Text] [Related]
7. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Eddahibi S; Chaouat A; Morrell N; Fadel E; Fuhrman C; Bugnet AS; Dartevelle P; Housset B; Hamon M; Weitzenblum E; Adnot S Circulation; 2003 Oct; 108(15):1839-44. PubMed ID: 14530202 [TBL] [Abstract][Full Text] [Related]
8. [Correlation between serum marker variations and pulmonary hypertension secondary to chronic obstructive pulmonary disease]. Xie X; Wang X; Zhang Y; Han D; Li S; Li M Nan Fang Yi Ke Da Xue Xue Bao; 2013 Oct; 33(10):1458-62. PubMed ID: 24144746 [TBL] [Abstract][Full Text] [Related]
9. Is systemic inflammation responsible for pulmonary hypertension in COPD? Sin DD; Man SF Chest; 2006 Aug; 130(2):310-2. PubMed ID: 16899824 [No Abstract] [Full Text] [Related]
10. [Gene polymorphism of the endothelial nitric oxide synthase enzyme and pulmonary hypertension in patient with chronic obstructive pulmonary disease]. Sun LR; Wang C; Wu AQ; Yan BM; Li DM; Zhang JL; Wang GJ; Zhang Y; Li XQ; Zhang QZ Zhonghua Jie He He Hu Xi Za Zhi; 2008 May; 31(5):335-40. PubMed ID: 18953956 [TBL] [Abstract][Full Text] [Related]
11. High levels of interleukin-6 and 8-iso-prostaglandin in the exhaled breath condensate and serum of patients with chronic obstructive pulmonary disease related pulmonary hypertension. He H; Tao Y; Chen X; Qiu H; Zhu J; Zhang J; Ma H Chin Med J (Engl); 2014; 127(9):1608-12. PubMed ID: 24791862 [TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus. Tanaseanu C; Tudor S; Tamsulea I; Marta D; Manea G; Moldoveanu E Eur J Med Res; 2007 Apr; 12(4):145-51. PubMed ID: 17509958 [TBL] [Abstract][Full Text] [Related]
13. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Wright JL; Levy RD; Churg A Thorax; 2005 Jul; 60(7):605-9. PubMed ID: 15994270 [TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of the serotonin transporter, but not the 2a receptor or nitric oxide synthetase, are associated with pulmonary hypertension in chronic obstructive pulmonary disease. Ulrich S; Hersberger M; Fischler M; Nussbaumer-Ochsner Y; Treder U; Russi EW; Speich R Respiration; 2010; 79(4):288-95. PubMed ID: 19556740 [TBL] [Abstract][Full Text] [Related]
15. Echocardiographic Evaluation of the Relationship Between inflammatory factors (IL6, TNFα, hs-CRP) and Secondary Pulmonary Hypertension in patients with COPD. A Cross sectional study. Ansarin K; Rashidi F; Namdar H; Ghaffari M; Sharifi A Pneumologia; 2015; 64(3):31-5. PubMed ID: 26738368 [TBL] [Abstract][Full Text] [Related]
16. [Update on pulmonary hypertension in chronic obstructive pulmonary disease]. Onen ZP; Karabıyıkoğlu G Tuberk Toraks; 2010; 58(2):202-12. PubMed ID: 20865576 [TBL] [Abstract][Full Text] [Related]
17. World Health Organization Group III pulmonary hypertension. Poor HD; Girgis R; Studer SM Prog Cardiovasc Dis; 2012; 55(2):119-27. PubMed ID: 23009908 [TBL] [Abstract][Full Text] [Related]
18. Mendelian randomization study of interleukin-6 in chronic obstructive pulmonary disease. van Durme YM; Lahousse L; Verhamme KM; Stolk L; Eijgelsheim M; Loth DW; Uitterlinden AG; Breteler MM; Joos GF; Hofman A; Stricker BH; Brusselle GG Respiration; 2011; 82(6):530-8. PubMed ID: 21997388 [TBL] [Abstract][Full Text] [Related]
19. [Pulmonary hypertension associated with COPD: some issues should be focused on]. Zhai ZG; Xie WM; Yang YH Zhonghua Jie He He Hu Xi Za Zhi; 2008 May; 31(5):323-4. PubMed ID: 18953953 [No Abstract] [Full Text] [Related]
20. [The relationship between inflammatory mediators and pulmonary hypertension in patients with chronic obstructive pulmonary disease]. Jiang YW; Pang L; Fang QH; Ma YM Zhonghua Jie He He Hu Xi Za Zhi; 2011 Dec; 34(12):904-8. PubMed ID: 22333502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]